With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Quote this valuation with its source: Fair value, Potential value and the price at analysis.
FAQ
STE — frequently asked questions
Is STERIS plc overvalued?
In our latest published analysis dated 2026-10-09, STE trades close to fair value. The price recorded at analysis is USD 214 versus our fair value of USD 210; the high endpoint is presented separately as potential value of USD 250. That implies roughly 2.3% downside to fair value at that date.
Our latest published report, analyzed 2026-10-09, gives STE a fair value of USD 210 and a potential value of USD 250. The conclusion is triangulated across multiple valuation models and weighted by reliability for STERIS plc's archetype; it is a dated research output, not a live price.
Should I buy STE now?
Our latest published rating for STE, analyzed 2026-10-09, is Hold. STERIS plc trades close to fair value at the analysis-date price of USD 214 versus fair value of USD 210; potential value is USD 250. This is research for educational purposes, not personalized investment advice.
What are the biggest risks for STE?
The dedicated bear-case section in our report analyzed 2026-10-09 documents STERIS plc's material risks, evidence, thresholds, and thesis-invalidation conditions. Scenario-specific explanations remain in that section so the report does not repeat or decontextualize them elsewhere.
What is STE's rating?
Our latest published rating for STE, analyzed 2026-10-09, is Hold, with a published moat assessment of 9/10 (Wide). It reflects our fair value of USD 210, the potential value of USD 250, and the price recorded at analysis (USD 214).
Accelerated normalization of biopharmaceutical customer destocking coupled with rapid procedural expansion in endoscopy, driving high-margin proprietary chemistry pull-through and automated North Carolina facility scaling toward Potential value of $249.66,,.
Main risk
Acute care hospitals freezing capital equipment budgets or biopharmaceutical customers prolonging inventory destocking past H2 FY2027,.
We maintain a Hold rating on STERIS plc (STE) with a Fair value of $209.55 and Potential value of $249.66 against a report-date share price of $214.40 as of October 9, 2026,. Primary downside risks (acute care capital equipment freezes and AST biopharma destocking duration) and a lack of valuation margin of safety, with shares trading at a 2.31% premium to Fair value (implied return of -2.26%), precede the bullish wide-moat thesis anchored by hospital endoscopy lock-in and contract sterilization network density, warranting patience until an attractive entry valuation or destocking inflection emerges,,,,.3,4
STERIS operates an advantaged business model characterized by mission-critical regulatory barriers and high recurring cash flows. In acute care hospitals and ambulatory surgery centers, its installed base of automated endoscope reprocessors and sterilizers drives continuous pull-through of dedicated chemistries and consumables,. In outsourced contract sterilization, strict regulatory validations make customer substitution virtually impossible, cementing long-term biopharmaceutical relationships.4,7
At the report-date share price of $214.40 as of October 9, 2026, STERIS trades at a 2.31% premium to its fundamental Fair value of $209.55 (representing an implied return of -2.26%). The company is actively investing ~$450M in FY2027 capital expenditures to consolidate operations into an automated greenfield facility in North Carolina,. While this project expands long-term capacity, near-term free cash flow is temporarily constrained and customer destocking in AST continues to weigh on first-half volumes.3,4
We conclude that while STERIS is an exceptional compounder with an ROIC of 9.33% outpacing its 8.60% WACC, the current valuation adequately reflects its near-term earnings power. Investors should hold existing allocations and wait for a wider margin of safety before deploying new capital.1
Durable Switching Costs in Hospital Endoscopy Reprocessing
STERIS's installed base of automated endoscope reprocessors in acute care hospitals and ambulatory surgery centers creates captive demand for high-margin proprietary chemistries and single-use consumables, supporting resilient recurring revenue.4
High Regulatory Barriers and Network Density in Contract Sterilization
The AST segment operates terminal contract sterilization under stringent FDA device master files, making customer switching cumbersome while upcoming North Carolina capacity expansion resolves site volume limits,.4
Insulation from Direct Therapeutic Medtech Innovation Risk
Unlike device makers competing on implant efficacy, STERIS provides foundational sterilization infrastructure consumed by medtech manufacturers and healthcare providers alike, insulating it from therapeutic displacement.4
House recommendation
Primary downside risks from acute care capital equipment freezes and prolonged AST biopharma destocking duration, combined with a lack of valuation margin of safety as shares trade at $214.40 on October 9, 2026, representing a 2.31% premium to Fair value of $209.55 (implied return of -2.26%), take precedence over the company's bullish wide-moat thesis,,,. While STERIS remains an exemplary healthcare compounder supported by a Wide economic moat, superior cash conversion (converting net income into free cash flow), and mission-critical positioning across acute care procedures and outsourced medical sterilization,, the valuation leaves insufficient margin for execution missteps. We maintain a Hold rating, advising investors to maintain existing exposure while waiting for an attractive entry valuation or clear operational confirmation of an AST destocking inflection in the second half of FY2027.3
Company overview
STERIS plc is a leading global provider of infection prevention, sterile processing, and procedural surgical solutions serving acute care hospitals, ambulatory surgery centers, and pharmaceutical and medical device manufacturers. The company generated $5,935.9M in consolidated revenue in FY2026, operating through three primary reporting segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences.
The Healthcare segment is the largest business unit, generating $4,208.6M (70.9% of FY2026 revenue). Healthcare delivers steam sterilizers, surgical tables, automated endoscope reprocessors, and high-margin recurring chemistries and single-use consumables. The Applied Sterilization Technologies segment generated $1,138.5M (19.2% of FY2026 revenue), providing contract gamma, electron-beam, and ethylene oxide terminal sterilization services to medical device and biopharmaceutical manufacturers. The Life Sciences segment generated $588.8M (9.9% of FY2026 revenue), offering specialized washing systems, vaporized hydrogen peroxide equipment, and cleaning chemistries.
In a stress test where acute care hospitals institute capital procurement freezes and biopharmaceutical customer destocking extends through FY2028, consolidated revenue growth contracts by 5 percentage points over five years and operating margins compress by 300 basis points due to fixed sterilization overhead under-absorption. Under this stress scenario, compounded by terminal valuation multiple compression toward equipment peers (14.4x forward P/E), intrinsic fair value falls toward $179.45. Even under these adverse conditions, STERIS's high proportion of recurring revenue (>80% from consumables, chemistries, and service contracts) provides an operating cash flow floor, and modest net debt of $1,373.2M prevents balance-sheet distress.
STERIS's wide competitive moat derives from its deeply entrenched positioning across hospital sterile processing departments and contract medical device sterilization networks. In healthcare facilities, surgical instrumentation and flexible endoscopes must undergo rigorous, validated cleaning and high-level disinfection between every patient procedure. STERIS provides the capital equipment—including automated endoscope reprocessors, steam sterilizers, and washer-disinfectors—that anchors hospital central sterile processing departments. Once installed, these systems require proprietary chemistries, biological indicators, and specialized maintenance contracts, creating high customer switching costs and a predictable annuity stream that represents the majority of segment revenue,.
In contract sterilization, the Applied Sterilization Technologies (AST) segment benefits from formidable regulatory intangible assets and geographic network density. Medical device and biopharmaceutical manufacturers validate their terminal sterilization modalities through specific STERIS irradiation and gas processing facilities. Switching sterilization providers requires updating regulatory filings with health authorities, completing extensive microbiological lethality validations, and re-qualifying logistics chains. This regulatory lock-in results in multi-year contract renewals and exceptional pricing power, shielding the business from direct price competition and providing insulation against broader medtech device cycles.
The highlighted cell is Fair value when every assumption sits at its base level ($209.55). Each row and column shows what Fair value becomes when one assumption moves.
Free cash flow to the firm stays positive in the first projected year at $594.2M after modeled reinvestment of $319.9M, with terminal value at 79.2% of enterprise value. A sudden drop in free cash flow is not projected unless capital spending relative to , reinvestment, or resets materially.
Upgrade the rating; Re-examine facility utilization rates and biopharmaceutical production schedules; consider expanding capital allocation as operational momentum confirms faster margin trajectory.
An upside surprise driven by rapid customer destocking abatement in AST and accelerated automated endoscope reprocessor chemistry pull-through would validate faster operational leverage, justifying an upgrade.
In-line
Maintain Hold; Maintain existing allocations without adding fresh capital; monitor customer destocking progress into the second half and evaluate greenfield facility construction milestones.
Trigger: Reported and operational earnings tracking within full-year ranges with steady mid-single-digit underlying organic expansion.
Industry capex-to-revenue stands at 4.5% and capex-to-depreciation is 0.8x. STERIS is out-investing the industry baseline, with FY2026 capex of $369M (6.22% of revenue), and FY2027 capex guided to approximately $450M (~7.06% of expected revenue). This elevated reinvestment funds greenfield AST consolidation in North Carolina to alleviate capacity limits and automate processing,.4,6
Bull cycle
A synchronized surge in global surgical procedure volumes and rapid resolution of biopharma customer destocking drive mid-to-high single-digit revenue growth. New hospital operating rooms and ambulatory surgery centers adopt STERIS automated reprocessing systems, driving high-margin proprietary chemistry consumption and double-digit operating profit expansion.
Bear cycle
Hospital operating margin compression leads to procurement freezes on high-ticket capital sterilizers and washers, while biopharma manufacturing slowdowns prolong sterilization destocking. Compounded by sustained $14M quarterly tariff costs and facility startup dual-running costs, margins compress toward industry baselines (15.5%).
§11 Position management
Sizing
2-3%
Given the Hold rating with the report-date share price ($214.40) trading close to Fair value ($209.55),, existing allocations should be held without deploying new capital. A 2-3% weighting reflects STERIS's high business quality and wide moat while recognizing that valuation offers limited margin of safety until an entry discount emerges.3
Risk
STERIS benefits from defensive qualities with over 80% recurring revenue, limiting severe fundamental drawdowns. Position risk should be managed by maintaining exposure within target portfolio limits, monitoring AST destocking resolution checkpoints, and adhering to disciplined entry price thresholds before increasing capital allocation.
§12 Investor perspectives
Value
Hold
With shares trading at 19.16x forward earnings and a 2.31% premium to Fair value ($209.55), STERIS offers insufficient margin of safety for value-focused buyers. Value investors should hold existing positions and wait for pullbacks toward $180-$190.3
Growth / Quality Compounder
Hold
STERIS possesses exceptional compounder attributes, including a Wide moat, high recurring consumable mix (>80%), and expanding operating margins. However, with current valuation leaving little room for execution missteps during the North Carolina facility buildout, holding existing weight is the prudent stance.4
Income / Tactical
Hold
A modest dividend yield and elevated FY2027 ($450M) limit near-term yield expansion. Tactical investors should hold and wait for clear H2 destocking inflection catalysts before increasing exposure.
§14 Final recommendation
Action
Hold
STERIS is a wide-moat compounder trading at $214.40 as of October 9, 2026, representing a 2.31% premium to its fundamental Fair value of $209.55 (implied return of -2.26%). While the business benefits from high switching costs in hospital endoscopy reprocessing and contract sterilization network density, the current market valuation fairly prices near-term growth, warranting a Hold rating.3
Investors should maintain current positions while awaiting a wider margin of safety (entry below $190) or clear evidence of an AST volume inflection in H2 FY2027.
§15Your notes
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Private notes
Visible only to you. Synced to this device.
0 chars
Sources
The records this analysis drew on, as they stood when it was run.
Geographically, STERIS generated $4,333.8M in the United States, $1,493.7M in Other Foreign Locations, and $108.5M in Ireland. More than 80% of total revenue is derived from recurring consumables, dedicated chemistries, and long-term service contracts.
The downside scenario reflects the compounding impact of acute care hospital capital spending freezes and prolonged biopharmaceutical inventory destocking. Under this path, high-margin capital equipment installations stall, contract sterilization volumes experience fixed cost under-absorption, and persistent import tariffs erode operating profitability without the benefit of timely price realization.
Ways this thesis can break
Prolonged Biopharma Destocking and Capacity Freeze in AST
Management reaffirmed AST organic growth of 7%-8% predicated on customer destocking subsiding in H2 FY2027,. If biopharma customer destocking persists into FY2028 and existing facility capacity limits bite before the North Carolina greenfield plant ramps, AST growth falling below 4% triggers fixed overhead under-absorption, slashing consolidated operating margin by 300 bps.4
FV impact
0%
Operating margin 3 points lower throughout
Trigger
Within 12 months
Hospital Capital Budget Freezes and Procedural Reprocessing Deferrals
Healthcare capital equipment revenue grew only 1% in Q1 FY2027 due to timing of shipments. If acute care hospitals institute capital equipment freezes due to macroeconomic reimbursement pressure, capital sales turn negative, reducing consolidated revenue growth by 5 percentage points across the 5-year forecast horizon.4,7
FV impact
-2.1%
Revenue and EPS growth 5 points lower for five years
STERIS currently trades at a forward P/E of 19.16x while medtech equipment peers GE HealthCare and Boston Scientific trade at forward P/Es of 12.15x and 12.63x, respectively,. A 20% contraction in STERIS terminal multiple from 18.0x toward peer levels reduces forward earnings equity value proportionally.2,3
FV impact
0%
Terminal multiple 20% lower
Trigger
Within 12 months
Early-warning signals to monitor
The five developments that would weaken our investment case.
01
Healthcare Capital Equipment Order Intake and Segment Growth
Signals acute care hospital capital spending freezes and deferral of sterilizer replacement cycles, impairing installed-base expansion needed for proprietary chemistry pull-through.
Current:1% capital equipment revenue growth and 4% order growth in Q1 FY2027
Alert ifNegative capital equipment order growth (<0% YoY) for two consecutive quarters or segment organic growth <4%
Indicates biopharma customer destocking has extended into structural volume loss and existing facility capacity limits have bound before North Carolina ramps, triggering fixed cost under-absorption.
Current:Tamped down in H1 FY2027 by comparisons and destocking; guided to 7%-8% for full year,
Demonstrates that tariff refunds and localized production adjustments are insufficient to prevent cross-border margin erosion across Other Foreign Locations.
Current:Consolidated EBIT margin expanded 100 bps YoY to 23.8% in Q1 FY2027
Alert if>150 bps international operating margin drag from tariff friction
STERIS generates consistent economic profit with ROIC of 9.33% exceeding its computed WACC of 8.60% (computed cost of equity of 9.0044% and pre-tax cost of debt of 5.76%,,). This positive spread of 73 bps on invested capital is sustained across economic cycles due to the mission-critical, regulatory-mandated nature of sterilization and surgical procedure volumes.1
9/ 10
Wide
Sources of advantage
01Switching Costs — In acute care hospitals and ambulatory surgery centers, STERIS's installed base of automated endoscope reprocessors and steam sterilizers creates severe operational switching barriers. These machines require dedicated proprietary chemistry formulations and certified consumables, locking healthcare systems into multi-year recurring purchases. Replacing an installed sterile processing department involves massive capital outlays, staff retraining, and clinical re-validation.Wide
02Regulatory Intangible Assets and Network Density — The Applied Sterilization Technologies (AST) network operates contract gamma, electron-beam, and ethylene oxide sterilization facilities under rigid FDA, EMA, and ISO validation protocols. Medical device and biopharma manufacturers file device master files referencing specific STERIS facilities; altering a sterilization partner requires extensive regulatory re-submissions and validation testing taking 12 to 24 months.Wide
03Scale and Distribution Infrastructure — With $5,935.9M in FY2026 revenue and $4,208.6M in Healthcare, STERIS maintains unmatched clinical service distribution, embedded technicians, and field engineering across thousands of acute care hospitals and ambulatory surgery centers globally.Moderate
Alternative Low-Temperature and In-House Hospital Sterilization Technologies
low
5 to 10 years
STERIS actively innovates in vaporized hydrogen peroxide (VHP) and automated reprocessing while maintaining extensive patent estates and regulatory clearances.
Environmental Regulatory Scrutiny on Ethylene Oxide (EtO) Emissions
medium
2 to 4 years
STERIS has proactively upgraded emission capture systems across its AST footprint, invested in radiation sterilization modalities (accelerator e-beam/X-ray), and consolidated operations into modern compliant facilities like North Carolina.4
Hospital Purchasing Group Scrutiny and Equipment Procurement Deferrals
medium
1 to 3 years
Consumables and recurring service agreements represent over 80% of revenue, shielding operating earnings even when capital equipment purchases face budgetary scrutiny.4
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and at , then adjust for signed per current share.
Operating margins expanding steadily supported by operating cost discipline and favorable procedural mix
AST customer destocking subsiding in the second half of the fiscal year in line with management expectations
Capital expenditures normalizing toward maintenance requirements following greenfield facility completion
The modal base case, carrying probability 60.0% and target $209.55 yielding an implied return of -2.3%, reflects steady execution across acute care hospital reprocessing and contract sterilization. STERIS delivers mid-to-high single-digit revenue growth while operating margins expand steadily toward target levels, balancing elevated near-term facility capex against durable cash generation.
Early operational efficiencies and labor savings from the automated greenfield facility consolidation
Complete tariff cost mitigation through commercial price increases and successful refund claims
Under the bull case, with probability 20.0% and target $249.66 yielding an implied return of 16.4%, customer inventory destocking in contract sterilization resolves ahead of schedule while automated endoscope reprocessor share gains accelerate. Operating margins expand beyond historical peaks as the automated North Carolina facility ramps, driving double-digit operational earnings growth.
Meeting base operational expectations confirms that procedural volume growth and tariff mitigation efforts are proceeding according to plan without altering the composite valuation.
Miss
Downgrade the rating; Reduce exposure or tighten portfolio risk controls; scrutinize hospital capital equipment backlog conversions and audit tariff cost absorption before reassessing fundamental value.
Trigger: AST organic revenue growth decelerating below historical baselines accompanied by flat or contracting healthcare capital equipment shipments and gross margin contraction.
A material shortfall would indicate that biopharma customer destocking has transitioned into structural volume loss or that acute care hospital procurement freezes are constraining high-margin installations.
Earnings quality is supported by a heavy concentration in recurring consumables, dedicated chemistries, and service contracts across acute care hospitals and contract sterilization facilities. Operating cash generation comfortably exceeds net income, reflecting disciplined working capital control and consistent non-cash depreciation add-backs. Receivables turnover tracks procedural cadence smoothly, while inventory build-up remains tied to temporary safety stock buffering and greenfield facility staging rather than channel stuffing. Pricing realization and active tariff refund filings have successfully shielded operating profit from gross margin degradation.
Estimate momentum
Consensus revisions following recent earnings releases have remained remarkably steady. Sell-side analysts maintained revenue and diluted earnings expectations for both FY2027 and FY2028 with virtually unchanged headline projections, reflecting broad alignment with management's reaffirmed guidance. Minor upward drift in out-year consensus reflects anticipated volume normalization in contract sterilization rather than speculative multiple expansion.
CurrentManagement reaffirmed full-year organic growth expectations, anticipating a volume inflection in the second half of the fiscal year.
Why it matters
AST organic volume throughput directly drives fixed facility overhead absorption and carries the highest divisional operating margins across the enterprise.
02
Metric:
Healthcare Endoscopy Consumables and Dedicated Chemistry Growth
CurrentConsumables demand continues to outpace overall hospital spending, driven by procedural expansion and market share gains in automated endoscope reprocessors.
Why it matters
High-margin proprietary chemistries and single-use consumables create an annuity stream that expands segment operating margins and insulates cash flow.
03
Metric:
Healthcare Capital Equipment Backlog and Order Conversion
CurrentOrder intake remains solid with an expanding backlog, though shipment scheduling created modest near-term revenue lumpiness.
Why it matters
Shipment timing of steam sterilizers and surgical tables dictates quarterly equipment revenue and seeds the future installed base for recurring chemistries.
04
Metric:
North Carolina Greenfield Facility Construction and Capex Trajectory
CurrentCapital expenditures remain elevated in line with management targets as facility construction advances toward consolidation milestones.
Why it matters
Timely operational launch is required to alleviate upper capacity constraints at existing sterilization facilities and drive labor automation efficiencies.
05
Metric:
Net Tariff Cost Absorption and Commercial Price Realization
CurrentActive pricing increases and phase one and two refund claims have largely neutralized quarterly tariff friction, preserving gross margin stability.
Why it matters
Unmitigated import tariffs exert direct pressure on manufactured equipment gross margins unless neutralized by contractual price escalators and refund claims.
Free cash flow conversion is robust, with FY2026 FCF of $972.4M representing 124.3% conversion of GAAP net income ($782.3M),. In Q1 FY2027, operating cash flow was $367.1M. While the FY2027 capex bump to $450M temporarily tempers FCF, normalized owner earnings power is $1,010.5M ($10.36 per share), supporting strong compounder dynamics.5,6
In FY2026, STERIS generated $1,341.4M in operating cash flow and invested $369.0M in capital expenditures, yielding $972.4M in free cash flow. FY2027 capital allocation is dominated by ~$450M in capex for network facility consolidation and automation. Net debt stands at $1,373.2M against market capitalization of $20.90B, representing a conservative debt weight of 8.91%.
ROIC is positioned to expand over the medium term. As the elevated FY2027 capital expenditure of $450M for the North Carolina plant completes, capital intensity normalizes and automated labor efficiencies take hold, lifting ROIC further above WACC.
ROIC of 9.33% exceeds computed WACC of 8.60% by 73 bps, confirming structural value creation.
Strong Cash Conversion Supported by Consumables and Chemistries
FY2026 operating cash flow of $1,341.4M and FCF of $972.4M easily fund annual maintenance requirements.
The high proportion of recurring revenue provides defensive cash flow resilience during periods of hospital capital procurement delay.
FY2027 capex increases to approximately $450M, raising reinvestment rate to 35% before fading toward 23% by FY2031.
High upfront automation and consolidation costs in North Carolina will depress near-term free cash flow before delivering operational scale and lower operating labor requirements.
Q1 FY2027 EBIT margin reached 23.8%, expanding 100 bps year-over-year, while FY2026 operating margin was 18.56%.
Demonstrates pricing power and operational discipline capable of absorbing $14M in quarterly tariff headwinds to achieve the 20.2% terminal operating margin forecast.
Income statement breakdownHow business scale converts into reported profit.Jun 30, 2026
StockMarketAgent.AI
Revenue$1.5BCost of revenue−$808.6MGross profit$684.2MOperating expenses−$398.3MOperating income$285.8MNon-operating items and tax−$84.8MNet income$201M
Financial history data
Revenue
$1,492,700,000
Cost of revenue
$808,600,000
Gross profit
$684,200,000
Operating expenses
$398,300,000
Operating income
$285,800,000
Non-operating items and tax
-$84,800,000
Net income
$201,000,000
Balance sheet snapshotHow reported assets are held and financed at the selected period.
StockMarketAgent.AI
Assets held asFinanced by
Total assets$10.7BCash$439.6MCurrent assets$2.4BTotal liabilities$3.5BCurrent liabilities$1.1BShareholders’ equity$7.2B
Balance sheet breakdown data
Total assets
$10,737,200,000
Cash
$439,600,000
Current assets
$2,394,600,000
Total liabilities
$3,540,000,000
Current liabilities
$1,145,000,000
Shareholders’ equity
$7,197,200,000
Cash-flow statement breakdownHow cash moved through operating, investing, and financing activities in FY2026.
StockMarketAgent.AI
Operating cash reconciliation
Net income$782.3MDepreciation and amortization+$486.5MStock-based compensation+$61.7MOther operating adjustments+$10.9MOperating cash flow$1.3B
STERIS plc (STE) trades at 19.2x forward earnings against a peer median of 19.0x. Its EV/EBITDA of 13.5x compares with a peer median of 17.6x. The comparison uses 4 peers: GE HealthCare Technologies Inc., DexCom Inc., Boston Scientific Corporation and Edwards Lifesciences Corporation, as of 2026-10-08 to 2026-10-09.
Secular trends
Trend
Impact
Note
Expansion of Outpatient and Ambulatory Surgery Centers (ASCs)
positive
Migration of surgical procedures from inpatient hospital settings to outpatient ASCs requires new automated endoscope reprocessors and compact sterile processing footprints, expanding STERIS's addressable equipment and chemistry market.
Supply Chain Regionalization, Onshoring, and Biopharma Localization
positive
Global pharmaceutical and medical device manufacturers are duplicating production facilities across North America and Europe to navigate tariff barriers and supply risks, creating additive demand for decentralized contract sterilization across STERIS's network.
Rising Regulatory Standards for Flexible Endoscope Reprocessing
positive
Stringent FDA guidelines and infection-control mandates enforce automated cleaning and high-level disinfection protocols, accelerating the replacement of manual cleaning with STERIS automated reprocessors and dedicated chemistries.
Global Trade Friction and Input Tariff Inflation
negative
Persistent tariffs on imported manufacturing components create structural friction of $14M per quarter ($56M annually), requiring ongoing pricing adjustments and productivity offsets to prevent gross margin erosion.
Positioning
STERIS occupies an advantaged position at the nexus of acute care sterile processing and contract terminal sterilization. Unlike pure-play device peers (BSX, DXCM, EW) exposed to clinical development risks and therapeutic obsolescence, STERIS functions as indispensable infrastructure. Its operating margin of 18.56% in FY2026 already exceeds the medical equipment industry average of 15.5%, and its customer lock-in insulates it from direct product substitution.6
Entry tranches
Level
Action
Why
$180 - $190 (representing a 10-15% discount to Fair value of $209.55)
Initiate incremental accumulation or add to existing position
Provides an adequate margin of safety below intrinsic Fair value while absorbing potential near-term destocking delays.
$200 - $210 (near Fair value of $209.55)
Hold existing exposure; do not add fresh capital
Shares trade near fair value, offering balanced risk-reward with limited mispricing.
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
Discounted forecast-period cash flows ($31.37) plus discounted terminal value ($119) minus signed net debt per current share ($14.08) equals the $136 lens value shown above. Negative net debt is net cash, so subtracting it raises value.
